FREMONT, California – June 18, 2014 – Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced the pricing of its initial public offering of 4,286,000 shares of common stock at a public offering price of $14.00
Study will evaluate tenapanor for the treatment of hyperphosphatemia in ESRD patients on hemodialysis FREMONT, Calif., May 15, 2014/PRNewswire/--Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced that it has
FREMONT, CALIFORNIA. FEBRUARY 24, 2014 – Ardelyx, Inc. today announced that it has licensed to Sanofi (NYSE: SNY; EURONEXT: SAN) its novel phosphate transport NaP2b inhibitor program (also known as NaPi2b, Npt2b and SLC34A2). Ardelyx will receive an undisclosed upfront payment from
FREMONT, CALIFORNIA. JANUARY 13, 2014 – Ardelyx, Inc. today announced it has received $15 million USD from AstraZeneca (NYSE:AZN, LON:AZN), representing a development milestone that was part of the collaboration agreement the companies had previously executed.
AstraZeneca and Ardelyx today announced a worldwide exclusive licensing agreement for Ardelyx’s NHE3 inhibitor programme, including the Phase 2-ready lead compound RDX5791, for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease
RDX5791, A NON-SYSTEMIC NHE3 INHIBITOR, ALONE OR IN COMBINATION WITH ENALAPRIL, PREVENTS CARDIOVASCULAR AND RENAL DYSFUNCTION IN SALT FED RATS WITH RENAL INSUFFICIENCY Andrew G. Spencer1, Marc Navre1, Craig F. Plato2, Kristin M. Joly2, Kevin Ida2, Eric D. Labonte1, Jeffrey W.
FREMONT, CALIFORNIA. AUGUST 31, 2011 – Ardelyx, Inc. today announced it has appointed Mr. Kaufmann to the newly created position of Chief Business Officer. Mr. Kaufmann’s role will include business and corporate development, licensing, and strategic planning. Mr.
Ardelyx, Inc. Closes $30M Series B Financing FREMONT, CALIFORNIA. AUGUST 31, 2011 – Ardelyx, Inc. today announced it has closed a Series B preferred stock financing of $30.0 million. Participating in the Series B financing are previous investors in the Company, NEA, CMEA and certain